The purpose of this study is to measure the prostaglandin levels in patients with stress ulcer and the effect of Prevacid on prostaglandin levels in patients with stress ulcer.
Effect of Prevacid on Prostaglandin Levels in the Gastric Mucosa of Patients With Stress Ulcer.
- Stomach Ulcer
Treatment, Randomized, Open Label, Active Control, Parallel Assignment, Efficacy Study.
Primary Outcome Measures:
- The effect of Prevacid on prostaglandin levels at 8 weeks
Secondary Outcome Measures:
- Esophagogastroduodenal endoscopy(EGD) with biopsy at day 1; EGD with biopsy at 8 weeks
The prostaglandin system plays an important role in the gastric mucosa to strengthen its resistance against injury. Critically ill patients are at greatest risk of developing stress-related gastric mucosal lesions. Although the levels of prostaglandins in gastric mucosa in patients with stressed animal has been studied, prostaglandin levels in the gastric mucosa in patients with stress ulcer have not been studied and the effect of Prevacid on prostaglandin levels in gastric mucosa from patients with stress ulcer is unknown.
We hypothesise that prostaglandin levels are low in the gastric mucosa in patients with stress ulcer, and Prevacid is an effective agents in increasing prostaglandin levels in the gastric mucosa in stress stress ulcer.
Comparison(s): The prostaglandin levels in patients who treated with Prevacid for stress ulcer, compared to the prostaglandin levels in patients who treated with H2 blocker for stress ulcer.
Eligibility & Criteria
- Ages Eligible for Study: 18 Years and older
- Genders Eligible for Study: Both
- Accepts Healthy Volunteers: No
- Patients in ICU with documented gastric stress ulcer by endoscopic examination, including patients with H. Pylori infection
- Patients have no known ulcer within 8 weeks prior to be admitted to ICU;
- Patients not on any PPI for 4 weeks prior to the study;
- Patients or family be consented for the study.
- Patients have gastric ulcer within 8 weeks prior to be admitted to ICU;
- Patients have gastric cancer confirmed by pathology;
- Patients on one of the PPIs already;
- Patients on any of the Non-steroidal Antiinflammatory Drugs
Qiang Cai, (MD, PhD)
Emory University School of Medicine
United States, 30322
All content and media on the HealthEngine Blog is created and published online for informational purposes only. It is not intended to be a substitute for professional medical advice and should not be relied on as health or personal advice. Always seek the guidance of your doctor or other qualified health professional with any questions you may have regarding your health or a medical condition. Never disregard the advice of a medical professional, or delay in seeking it because of something you have read on this Website. If you think you may have a medical emergency, call your doctor, go to the nearest hospital emergency department, or call the emergency services immediately.